Karyopharm Therapeutics (NASDAQ:KPTI) Receives Outperform Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $3.00 price objective on the stock.

Other analysts also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, January 15th. Piper Sandler boosted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $0.62 on Monday. Karyopharm Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.70. The stock has a market cap of $78.60 million, a PE ratio of -0.55 and a beta of 0.06. The firm has a fifty day moving average price of $0.69 and a 200 day moving average price of $0.78.

Institutional Trading of Karyopharm Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC grew its stake in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the last quarter. FMR LLC lifted its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares during the period. AQR Capital Management LLC grew its position in Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after buying an additional 622,194 shares during the last quarter. Geode Capital Management LLC increased its stake in Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after buying an additional 43,856 shares during the period. Finally, GSA Capital Partners LLP raised its position in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).